AbbVie Forecasts Positive Q1 Earnings Amid Strong Market Performance

AbbVie Inc. (ABBV), a biopharmaceutical company with a market capitalization of $309.7 billion, focuses on the research, development, and commercialization of medicines and therapies globally. Headquartered in North Chicago, Illinois, AbbVie’s product portfolio includes well-known drugs such as Humira, Skyrizi, Rinvoq, Imbruvica, and Venclexta/Venclyxto.

Upcoming Earnings Report

The company is expected to report its Q1 earnings on Friday, April 25, before the market opens. Analysts project an EPS of $2.38 per share, representing a 3% increase from the $2.31 reported in the same quarter last year. Notably, AbbVie has outperformed analysts’ earnings estimates for the past four quarters, with an adjusted EPS of $2.16 in the most recent quarter, which exceeded expectations by 1.4%. This strong performance is attributed to successes in its Immunology, Oncology, Neuroscience, and Aesthetics divisions.

Future Earnings Projections

Looking ahead, analysts anticipate that AbbVie will report an adjusted EPS of $12.31 for fiscal 2025, which would mark a 21.6% increase from $10.12 in fiscal 2024. In fiscal 2026, adjusted EPS is projected to rise by 13.5% year-over-year to $13.97.

Stock Performance Overview

In the past year, ABBV shares have increased by 4.5%, outperforming the S&P 500 Index, which gained 3.2%, and the Health Care Select Sector SPDR Fund (XLV), which fell by 2.9% during the same period.

Recent Earnings and Market Sentiment

Following its Q4 earnings release on January 31, ABBV shares jumped 4.7%. The company reported a 5.6% increase in net revenues, totaling $15.1 billion, driven by favorable performance across its immunology, oncology, neuroscience, and aesthetics product lines. Additionally, AbbVie offered a promising outlook, forecasting combined sales exceeding $31 billion from Skyrizi and Rinvoq by 2027, with expectations for high single-digit compound annual growth from 2025 to 2029.

Analyst Ratings and Price Targets

The consensus rating for ABBV stock is moderately optimistic, classified as a “Moderate Buy.” Among the 25 analysts covering the stock, 14 recommend a “Strong Buy,” two suggest a “Moderate Buy,” and nine opt for a “Hold” rating. The average price target of $210.62 indicates a potential upside of 20.3% based on current trading levels.

On the date of publication, Kritika Sarmah held no positions, either directly or indirectly, in any of the securities mentioned in this article. All information and data are provided solely for informational purposes. For further details, please view the Barchart Disclosure Policy here.

More news from Barchart

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.